Msm - NutraPedia

Back to Table of Contents

Research Overview

Human research on methylsulfonylmethane (MSM) in the studies reviewed here clusters into two main areas: (1) exercise-induced oxidative stress, inflammation, and muscle damage/recovery in generally healthy men, and (2) symptomatic management of osteoarthritis (OA), particularly knee OA. The exercise studies are small, randomized, double-blind, placebo-controlled trials using short supplementation periods (e.g., ~10 days at ~50 mg/kg/day before a 14 km run) or a small pilot dosing study over ~30 days (1.5–3.0 g/day) around a resistance-exercise muscle-damage protocol. OA evidence includes at least one randomized, double-blind, placebo-controlled knee OA trial using multi-gram daily dosing over 12 weeks, and MSM is also evaluated within a broader systematic review/meta-analysis of dietary supplements for OA. A separate clinical trial examined a topical combination product (MSM+EDTA) for lower-extremity pitting edema in chronic venous insufficiency, emphasizing oxidative stress markers and limb circumference outcomes.

The strongest evidence in these studies supports MSM’s capacity to modulate biochemical markers related to oxidative stress following acute exercise. Across the two 10-day running studies, MSM was associated with lower post-exercise oxidative stress markers (e.g., malondialdehyde, protein carbonyls, oxidized glutathione) and higher antioxidant capacity indices (e.g., glutathione status, total antioxidant capacity), alongside signals consistent with reduced muscle damage (e.g., lower creatine kinase and bilirubin at ~24 h post-exercise versus placebo). Evidence for clinically meaningful improvements in subjective recovery outcomes (soreness, fatigue) is suggestive but weaker, coming from a very small pilot study with trend-level findings and no clear performance benefit. For OA, MSM appears to produce statistically significant improvements in pain/function in the systematic review, but the review characterizes the clinical importance as unclear and notes that supplement effects generally diminish at medium- and long-term follow-up; thus, while MSM may help some OA symptoms short term, the magnitude and durability of benefit remain uncertain based on the summarized evidence.

Key gaps include the need for larger, adequately powered randomized trials with standardized dosing, longer follow-up, and clinically meaningful endpoints. In exercise contexts, replication in women, older adults, and trained athletes is needed, along with better linkage between biomarker changes and tangible outcomes (pain, function, return-to-training, performance). In OA, more high-quality trials should clarify effect size, responder subgroups, optimal dose and duration, comparative effectiveness versus established therapies, and longer-term safety and structural outcomes. For edema/venous insufficiency, the apparent benefit pertains to a topical MSM+EDTA combination (with MSM alone reportedly worsening swelling in that study), so additional trials are needed to disentangle MSM’s independent contribution, confirm reproducibility, and establish mechanism and safety for chronic use.

1. What conditions has Methylsulfonylmethane been studied for?

Exercise-induced muscle damage, oxidative stress, and recovery (after endurance running and resistance exercise) in healthy young men.
Knee osteoarthritis (OA) (pain, stiffness, physical function) in older adults.
Seasonal allergic rhinitis (SAR) (upper/lower respiratory symptoms, energy levels) in adults.
Lower extremity pitting edema in chronic venous insufficiency—studied as a topical combination product (MSM + EDTA), not MSM alone.

2. Does it work in treating those conditions? Summarize the evidence.

Exercise-induced muscle damage / oxidative stress: Evidence from small randomized, double-blind, placebo-controlled trials suggests MSM may reduce biochemical markers of oxidative stress and muscle damage after a 14 km run.
- In one trial (n=18; 10 days; 50 mg/kg/day), MSM was associated with lower creatine kinase (CK) and lower bilirubin at 24 h post-exercise versus placebo, and higher total antioxidant capacity (TAC) at multiple post-exercise timepoints (including significant differences vs placebo at 2 h and 24 h).
- In a similar trial (n=18; 10 days; 50 mg/kg/day), MSM maintained lower malondialdehyde (MDA), protein carbonyls (PC), and oxidized glutathione (GSSG) after exercise versus placebo, and increased reduced glutathione (GSH) and the GSH/GSSG ratio.
- A pilot resistance-exercise study (n=8; 30 days; 1.5 g/day vs 3.0 g/day) found only trends toward less soreness and fatigue (p values ~0.07–0.09), a significant post-exercise increase in antioxidant capacity (TEAC) with 3.0 g/day, and no significant improvement in performance (total work) or glutathione.
- Limitations: very small sample sizes; short duration; outcomes largely surrogate biomarkers (oxidative stress markers, CK) rather than clear functional outcomes; limited replication across diverse populations (e.g., women, older adults, trained athletes).
Knee osteoarthritis: Evidence suggests small improvements in some patient-reported outcomes, with uncertain clinical importance.
- In a randomized, double-blind, placebo-controlled trial (n=49; 12 weeks; 1.125 g three times daily), MSM showed significant between-group differences over time for WOMAC physical function and WOMAC total score. WOMAC pain and stiffness differences did not reach conventional significance (both reported p=0.08). VAS pain showed a borderline significant difference (reported p=0.05). Authors concluded improvements were small and clinical significance uncertain.
- A systematic review/meta-analysis of supplements for OA (search through April 2017) reported MSM had statistically significant improvements in pain but of unclear clinical importance, and noted overall evidence quality across supplements ranged from very low to high (overall short-term effects across supplements were considered moderate but evidence quality was very low).
- Limitations: modest sample size; effect sizes may be small; unclear durability beyond 12 weeks; heterogeneity across OA trials (dose, formulation, outcomes) in the broader literature.
Seasonal allergic rhinitis: Preliminary evidence suggests symptom improvement, but the study described is not clearly placebo-controlled.
- In a 30-day study (55 recruited; 50 completed; 2,600 mg/day), respiratory symptoms improved from baseline (upper/total by day 7; lower by week 3) and energy increased by day 14. However, IgE and histamine did not significantly change (histamine measured only in a subset, n=5), and the authors explicitly call for a larger randomized, double-blind, placebo-controlled trial.
- Limitations: without a clear placebo control and blinding, improvements could reflect placebo effects, regression to the mean, or natural symptom fluctuation across allergy season.
Lower extremity pitting edema (chronic venous insufficiency): Evidence supports a topical MSM + EDTA combination, not MSM alone.
- In a double-blind, placebo-controlled clinical trial of a lotion, calf/ankle/foot circumference declined after 2 weeks with MSM+EDTA but not placebo, and blood markers suggested reduced oxidative stress (FRAP and MDA changes). Notably, MSM alone increased swelling in the described second phase.
- Interpretation: the benefit appears attributable to the combination and/or EDTA; MSM alone may be counterproductive in this specific topical edema context (based on this study).

3. What health benefits does it have?

Antioxidant/oxidative stress modulation (exercise context):
- Increased antioxidant capacity markers after exercise (e.g., TAC increased post-run in the MSM group; TEAC increased post-resistance exercise at 3 g/day).
- Lower oxidative stress biomarkers after acute exercise (lower MDA, protein carbonyls, GSSG; higher GSH and GSH/GSSG ratio).
Potential reduction in exercise-related muscle damage markers:
- Lower post-exercise CK and bilirubin at 24 h in one small trial after 10 days of supplementation.
- Possible (but not definitive) reductions in perceived soreness and fatigue in a small pilot study (trends, not statistically robust).
Osteoarthritis symptom support (short term):
- Small improvements in WOMAC physical function and total score over 12 weeks in knee OA; systematic review suggests statistically significant pain improvement but unclear clinical importance.
Allergy symptom relief (preliminary):
- Reduced SAR symptom scores and improved energy over 30 days in an uncontrolled/unclear-control study; mechanism not supported by changes in IgE or histamine in that study.

4. Does it have any downsides or side effects?

Generally few side effects reported in the SAR study: The 30-day SAR study states “few side effects” with 2,600 mg/day, and references supportive toxicology data (details not provided in the study).
Potential worsening of swelling in a specific topical edema context: In the chronic venous insufficiency lotion trial, MSM alone increased swelling, while MSM+EDTA reduced swelling. This suggests MSM may be undesirable as a standalone topical agent for pitting edema (based on that study).
Osteoarthritis safety: The OA systematic review reported no differences between supplements and placebo for safety outcomes in general (exception noted for diacerein, not MSM). The knee OA MSM trial abstract does not highlight major safety signals.
Evidence limitations for safety: Most studies here are small and short (10–30 days for exercise studies; 12 weeks for OA). Rare adverse effects, long-term safety, and safety in pregnancy, kidney/liver disease, or polypharmacy are not addressed in these studies.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

No pharmacogenomic findings are reported in the studies reviewed here. None stratified outcomes by genotype or evaluated gene–supplement interactions.

What can be inferred: MSM influenced redox-related biomarkers (e.g., GSH/GSSG, MDA, protein carbonyls) in exercise studies, which are pathways that can be affected by genetic variation (e.g., antioxidant enzyme systems). However, no direct evidence from these studies supports genotype-specific benefit or harm.
Practical implication: At present, MSM use cannot be recommended or avoided on the basis of specific genetic variants based on these data alone.

MSM (Methylsulfonylmethane) Research Summaries

MSM Monograph Overview

A monograph for MSM would detail its chemical properties, biological effects, safety, and therapeutic uses. It is commonly used to treat pain, inflammation, and allergies. Dosages, side effects, and interactions are also discussed.

MSM in Treating Osteoarthritis

Research on MSM's effectiveness in treating osteoarthritis is inconclusive. While some studies show pain improvement, methodological issues such as proper dosage and treatment duration present challenges.

MSM Pharmacokinetics in Rats

MSM is rapidly absorbed, distributed across tissues, and excreted from the rat's body. Peak blood levels are reached within hours and the compound is fully cleared within 120 hours.

Quality Control of Supplements

Reflectance Near-Infrared (RNIR) spectroscopy, alongside chemometric techniques, can accurately measure levels of MSM in tablets, making it an effective quality control method for pharmaceuticals.

Consumer Choices in Natural Health Products

When choosing natural health products for osteoarthritis, consumers often value advice from health care providers over scientific evidence, indicating a contextual approach in decision-making.

MSM and DMSO as Solvents

Computational studies show that MSM and DMSO have high polarity and boiling points due to strong electrostatic sites on their sulfur atoms, explaining their solvent capabilities.

MSM in Plasma and Urine

Studies show that MSM can be detected in human plasma and urine, and its levels can be influenced by dietary intake, metabolism, and certain health conditions.

MSM and Osteoarthritis Pain Relief

MSM supplementation showed some improvements in pain and physical function in patients with knee osteoarthritis, but further research is needed to confirm long-term benefits and safety.

MSM and Cataract Management

Combining MSM with EDTA may offer a new approach for cataract management by enhancing antioxidant capacity and reducing lens cloudiness.

MSM Toxicity Studies

Toxicity studies in rats indicate that MSM is safe even at high doses, with no adverse effects or pathological changes observed.

MSM in Pregnancy

MSM administered to pregnant rats showed no signs of maternal or developmental toxicity, suggesting it is not harmful during pregnancy at tested doses.

References:

Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!